Literature DB >> 16865301

Adenosine concentration in great cardiac vein is increased in non-ventricular fibrillation dogs.

Kazuaki Uchino1, Toshiaki Ebina, Tohyoh Nihei, Tomoaki Ishigami, Toshiyuki Ishikawa, Kazuo Kimura, Satoshi Umemura.   

Abstract

This study was conducted to clarify the relationship between myocardial endogenous adenosine concentration in the great cardiac vein during ischemia and reperfusion-induced ventricular fibrillation (VF) and the occurrence rate of ischemia and reperfusion-induced VF. Sixty anesthetized mongrel dogs were subjected to 10-min left anterior descending artery occlusion and reperfusion. Blood from the great cardiac vein was sampled for the determination of adenosine and catecholamine concentrations. Hemodynamic parameters (blood pressure, lift ventricular dp/dt, left ventricular end-diastolic pressure, and cardiac output) were monitored throughout the experimental period. During coronary occlusion and reperfusion, VF occurred in 25 dogs (VF group). Ventricular fibrillation did not occur in 35 other dogs (non-VF group). Adenosine concentration in the great cardiac vein before the coronary occlusion did not differ between the two groups. However, the adenosine concentration in the great cardiac vein of the non-VF group significantly increased compared with that of the VF group (2,343 vs 65 pmol/ml, P = 0.026) during coronary occlusion and reperfusion. In contrast, hemodynamic parameters did not differ between the two groups. The study results demonstrated that adenosine concentration in the great cardiac vein was higher in the non-VF group than in the VF group, suggesting that myocardial endogenous adenosine may have a role in the suppression of ischemia and reperfusion-induced VF in dogs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865301     DOI: 10.1007/s00380-005-0881-1

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   1.814


  18 in total

1.  Automated analysis for plasma epinephrine and norepinephrine by liquid chromatography, including a sample cleanup procedure.

Authors:  A Yamatodani; H Wada
Journal:  Clin Chem       Date:  1981-12       Impact factor: 8.327

2.  An antiarrhythmic effect of adenosine during myocardial ischaemia and reperfusion.

Authors:  C L Wainwright; J R Parratt
Journal:  Eur J Pharmacol       Date:  1988-01-12       Impact factor: 4.432

Review 3.  Adenosine and cardioprotection in the diseased heart.

Authors:  M Kitakaze; T Minamino; K Node; S Takashima; H Funaya; T Kuzuya; M Hori
Journal:  Jpn Circ J       Date:  1999-04

4.  Endogenous adenosine reduces the occurrence of ischemia-induced ventricular fibrillation in rat heart.

Authors:  J Schreieck; G Richardt
Journal:  J Mol Cell Cardiol       Date:  1999-01       Impact factor: 5.000

5.  Adenosine infusion inhibits adenosine-induced cardiac actions but enhances acetylcholine-induced actions in isolated dog atria.

Authors:  Masato Tsuboi; Shigetoshi Chiba
Journal:  Heart Vessels       Date:  2003-03       Impact factor: 2.037

6.  Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia.

Authors:  G Richardt; W Waas; R Kranzhöfer; E Mayer; A Schömig
Journal:  Circ Res       Date:  1987-07       Impact factor: 17.367

Review 7.  Acute adenosinergic cardioprotection in ischemic-reperfused hearts.

Authors:  John P Headrick; Ben Hack; Kevin J Ashton
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-11       Impact factor: 4.733

8.  A simple and sensitive radioimmunoassay for adenosine.

Authors:  R Yamane; T Nakamura; E Matsuura; H Ishige; M Fujimoto
Journal:  J Immunoassay       Date:  1991

9.  Endogenous adenosine suppresses norepinephrine-induced ventricular arrhythmias in rat heart.

Authors:  B Görge; T Kurz; H A Katus; G Richardt
Journal:  Basic Res Cardiol       Date:  1998-08       Impact factor: 17.165

10.  Action of ATP on ventricular automaticity.

Authors:  G Stark; H Domanowits; F Sterz; U Stark; M Bachernegg; E Kickenweiz; M Decrinis; A N Laggner; H A Tritthart
Journal:  J Cardiovasc Pharmacol       Date:  1994-11       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.